Track Elite Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Elite Pharmaceuticals, Inc. ELTP · Stock Open Elite Pharmaceuticals, Inc. in new tab

0.2479 USD
P/E
5.75
EPS
0.04
P/B
2.37
ROE
74.31
Beta
0.33
Loading chart...
Key Metrics
Earnings dateNov. 12, 2026
P/E5.75
EPS0.04
Book Value0.10
Price to Book2.37
Debt/Equity5.32
% Insiders22.389%
Growth
Revenue Growth-0.20%
Earnings Growth-0.38%

DCF valuation

Model fair value for Elite Pharmaceuticals, Inc. (ELTP)
Result
Sign in to run the valuation for ELTP.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Elite Pharmaceuticals, Inc. Logo Elite Pharmaceuticals, Inc. Analysis (ELTP)

United States Health Care Official Website Stock

Is Elite Pharmaceuticals, Inc. a good investment? Elite Pharmaceuticals, Inc. (ELTP) is currently trading at 0.2479 USD.

In terms of valuation, the stock trades at a P/E ratio of 5.75. This relatively low multiple may signal that Elite Pharmaceuticals, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Elite Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 12, 2026.

Investor FAQ

Does Elite Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Elite Pharmaceuticals, Inc.?

Elite Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of 0.04.

Company Profile

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules to treat bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. It also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; Methotrexate Sodium 2.5mg tablets for the treatment of Antimetabolite under the Otrexup PF brand; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; Acetaminophen and Hydrocodone Bitartrate capsules for the treatment of pain under the Norco brand; Lisdexamfetamine Dimesylate to treat ADHD under the Vyvanse brand; Oxycodone Hydrochloride and Acetaminophen tablets to treat pain under the Percocet brand name; and Methadone Hydrochloride tablets for the treatment of pain under the Dolophine brand. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of allergy, bariatric, attention deficit, and infection. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Exchange Ticker
PNK (United States) ELTP
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion